{"version":"1.0","provider_name":"Global","provider_url":"https:\/\/www.ipsen.com\/fr\/","author_name":"IPSEN","author_url":"https:\/\/www.ipsen.com\/fr\/author\/ipsenadmin\/","title":"Les r\u00e9sultats de l\u2019essai pivot de Phase III ELATIVE\u00ae d\u2019Ipsen avec \u00e9lafibranor dans la PBC pr\u00e9sent\u00e9s comme donn\u00e9es de derni\u00e8re minute au congr\u00e8s de l\u2019AASLD et publi\u00e9s dans le New England Journal of Medicine","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"jcNPqY118g\"><a href=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/aasld_elative_fr\/\">Les r\u00e9sultats de l\u2019essai pivot de Phase III ELATIVE\u00ae d\u2019Ipsen avec \u00e9lafibranor dans la PBC pr\u00e9sent\u00e9s comme donn\u00e9es de derni\u00e8re minute au congr\u00e8s de l\u2019AASLD et publi\u00e9s dans le New England Journal of Medicine<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/aasld_elative_fr\/embed\/#?secret=jcNPqY118g\" width=\"600\" height=\"338\" title=\"&#8220;Les r\u00e9sultats de l\u2019essai pivot de Phase III ELATIVE\u00ae d\u2019Ipsen avec \u00e9lafibranor dans la PBC pr\u00e9sent\u00e9s comme donn\u00e9es de derni\u00e8re minute au congr\u00e8s de l\u2019AASLD et publi\u00e9s dans le New England Journal of Medicine&#8221; &#8212; Global\" data-secret=\"jcNPqY118g\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.ipsen.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"L&#8217;essai de phase III ELATIVE\u00ae confirme le potentiel du candidat-m\u00e9dicament \u00e0 l\u2019\u00e9tude, \u00e9lafibranor, en tant que nouvel double agoniste du PPAR \u03b1 et \u03b4, premier de sa classe pour les patients atteints de Cholangite Biliaire Primitive. Elafibranor a permis d&#8217;obtenir des am\u00e9liorations significatives des biomarqueurs de la progression de la maladie par rapport au placebo,","thumbnail_url":"https:\/\/ml-eu.globenewswire.com\/media\/ZmU3OWE4NmItYTZiZi00NzllLWI0MWUtYzJjMTRhMWJlZTg3LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png"}